# Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer

Source: https://onco.cc/trials/nct06873763/  
OnCo record `nct06873763` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Trifluridine/tipiracil, Bevacizumab in colorectal cancer, run by STCube, Inc., now recruiting.

## Summary

Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer is a phase 1/2 interventional study registered as NCT06873763 by STCube, Inc., with 52 participants planned, started 2025-06-09 and due to reach its primary completion in 2025-12. Interventions recorded: Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab. Conditions listed: Metastatic Colorectal Cancer (CRC), Recurrent Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06873763
- Phase: 1/2
- Setting: A Single-arm, Phase Ib/2 Study of Nelmastobart in Combination With Trifluridine/Tipiracil and Bevacizumab in Metastatic/Recurrent Colorectal Cancer Patients With Resistance or Intolerance to Oxaliplatin and Irinotecan-based Chemotherapy
- Sponsor: STCube, Inc.
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT06873763: https://clinicaltrials.gov/study/NCT06873763

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- companies: [STCube](https://onco.cc/companies/stcube/)

---
JSON: https://onco.cc/api/v1/entities/nct06873763.json